INTRODUCTION INTRODUCTION
A recent alert from the UK Committee on A recent alert from the UK Committee on Safety of Medicines stated that the dangers Safety of Medicines stated that the dangers of treatment of depression with paroxetine of treatment of depression with paroxetine outweigh the benefits in those under 18. outweigh the benefits in those under 18. Such a warning should focus our minds Such a warning should focus our minds on the evidence on which clinical practice on the evidence on which clinical practice is based. Antidepressant treatment of deis based. Antidepressant treatment of depression in the under-18s has been thought pression in the under-18s has been thought to be justified because clinical trials show to be justified because clinical trials show that it works so well in over-18s. But is that that it works so well in over-18s. But is that a reasonable assessment of the evidence? a reasonable assessment of the evidence? Kirsch Kirsch et al et al (2002) use the analogy of (2002) use the analogy of 'The Emperor's New Clothes' to describe 'The Emperor's New Clothes' to describe the findings from their meta-analysis of the findings from their meta-analysis of randomised placebo-controlled trials of randomised placebo-controlled trials of antidepressants. They conclude that antiantidepressants. They conclude that antidepressant medication appears to have only depressant medication appears to have only a small effect on outcome over and above a small effect on outcome over and above placebo. In this analogy psychiatry is the placebo. In this analogy psychiatry is the emperor, drug trials are the fraudsters and emperor, drug trials are the fraudsters and the deception is being revealed by a growthe deception is being revealed by a growing body of critical opinion proposing that, ing body of critical opinion proposing that, once methodological problems with clinical once methodological problems with clinical trials are taken into account, antideprestrials are taken into account, antidepressants either do not work at all or have an sants either do not work at all or have an effect that is so small as to be clinically effect that is so small as to be clinically unimportant (Andrews, 2001; Moncrieff, unimportant (Andrews, 2001; Moncrieff, 2002) . A large number of randomised 2002). A large number of randomised placebo-controlled trials of antidepressants placebo-controlled trials of antidepressants have been carried out over the past decades, have been carried out over the past decades, mostly funded by the pharmaceutical indusmostly funded by the pharmaceutical industry, and it is now recognised that about try, and it is now recognised that about 50% of negative trials go unpublished 50% of negative trials go unpublished (Thase, 1999) . Meanwhile, unipolar de-(Thase, 1999) . Meanwhile, unipolar depression has jumped into the top five of pression has jumped into the top five of the world's total burden of disease, and the world's total burden of disease, and there is an imperative need for effective there is an imperative need for effective and safe treatments. Do we need more and safe treatments. 
FOR FOR
Two papers published last year add weight to Two papers published last year add weight to an argument that efficacy data from clinical an argument that efficacy data from clinical trials no longer provide meaningful evidence trials no longer provide meaningful evidence about the utility of antidepressant drugs. about the utility of antidepressant drugs.
The first (Hypericum Depression Trial The first (Hypericum Depression Trial Study Group, 2002) reported an 8-week Study Group, 2002) reported an 8-week double-blind, randomised placebodouble-blind, randomised placebocontrolled trial of St John's wort and the controlled trial of St John's wort and the selective serotonin reuptake inhibitor serselective serotonin reuptake inhibitor sertraline. Despite substantive cell sizes, traline. Despite substantive cell sizes, neither drug was significantly different neither drug was significantly different from placebo in reducing depression severfrom placebo in reducing depression severity or disability or in overall improvement. ity or disability or in overall improvement. The second paper (Kirsch The second paper (Kirsch et al et al, , 2002) 2002) analysed efficacy data submitted to the US analysed efficacy data submitted to the US Food Food and Drug Administration for the and Drug Administration for the six 'most widely prescribed antidepressix 'most widely prescribed antidepressants' sants ' approved between 1987 and 1999. approved between 1987 and 1999. The mean drug-placebo difference (for 38 The mean drug-placebo difference (for 38 trials analysed) was two points on the trials analysed) was two points on the Hamilton Rating Scale for Depression, Hamilton Rating Scale for Depression, allowing the authors to conclude that antiallowing the authors to conclude that antidepressant drug effects were 'very small depressant drug effects were 'very small and of questionable clinical significance'. and of questionable clinical significance'. There is great difficulty reconciling such There is great difficulty reconciling such findings with clinical practice. findings with clinical practice.
A related question is whether clinical A related question is whether clinical trials provide any evidence that one type trials provide any evidence that one type of antidepressant therapy is superior to of antidepressant therapy is superior to any other. As reviewed earlier (Parker, any other. As reviewed earlier (Parker, 2001) , very large databases suggest that 2001), very large databases suggest that different classes of antidepressant drugs different classes of antidepressant drugs are equally efficacious. Meta-analyses also are equally efficacious. Meta-analyses also report similar response rates for drugs and report similar response rates for drugs and most non-drug treatments for depression. most non-drug treatments for depression. Robinson & Rickels (2002) reviewed about Robinson & Rickels (2002) reviewed about 60 psychotherapy studies and established 60 psychotherapy studies and established only trivial superiority of pharmacotherapy only trivial superiority of pharmacotherapy after controlling for the researcher's after controlling for the researcher's allegiance. The equipotency inference -that allegiance. The equipotency inference -that depression treatments are equally efficadepression treatments are equally efficacious and not distinctly superior to placebo cious and not distinctly superior to placebo -is hard to reject from such evidence.
-is hard to reject from such evidence.
The equipotency theory has obvious The equipotency theory has obvious implications. It fosters an 'affective fallacy' implications. It fosters an 'affective fallacy' in both therapists and patients -evaluating in both therapists and patients -evaluating therapies (particularly therapies (particularly their their therapy) imtherapy) impressionistically rather than by its integral pressionistically rather than by its integral strengths. High non-differential response strengths. High non-differential response rates allow therapists of many persuasions rates allow therapists of many persuasions to claim their therapy as efficacious and to claim their therapy as efficacious and scientifically proven. scientifically proven.
Conversely, failure of therapies to difConversely, failure of therapies to differentiate from placebo invites a challenge ferentiate from placebo invites a challenge that they act non-specifically, with Kirsch that they act non-specifically, with Kirsch et al et al (2002) Several factors have contributed to such Several factors have contributed to such uninformative results. First, the current uninformative results. First, the current classificatory model. Rather than distinclassificatory model. Rather than distinguishing separate depressive disorders guishing separate depressive disorders (phenotypically or aetiologically), 'depres-(phenotypically or aetiologically), 'depression' is currently modelled as a single entity sion' is currently modelled as a single entity varying only in severity. Creating pseudovarying only in severity. Creating pseudoentities such as 'major depression' for use entities such as 'major depression' for use as the principal 'diagnostic' measure inas the principal 'diagnostic' measure increases the chance of non-differential results creases the chance of non-differential results between interventions. between interventions.
Second, recruitment procedures have led Second, recruitment procedures have led to unrepresentative trial subjects. Formal and to unrepresentative trial subjects. Formal and informal screening excludes those with many informal screening excludes those with many comorbid conditions and the more 'biologicomorbid conditions and the more 'biological' depressive disorders (e.g. melancholia). cal' depressive disorders (e.g. melancholia). Inclusion and exclusion criteria ensure Inclusion and exclusion criteria ensure a pristine subject profile remote from a pristine subject profile remote from clinical practice, and inviting redefinition clinical practice, and inviting redefinition of 'cosmetic psychopharmacology'. of 'cosmetic psychopharmacology'.
Third, clinical trials remain subject to Third, clinical trials remain subject to bias, despite the efforts of researchers and bias, despite the efforts of researchers and the use of placebo-controlled designs. High the use of placebo-controlled designs. High non-specific 'responsivity' of trial subjects non-specific 'responsivity' of trial subjects is the fourth factor eroding their value. It is the fourth factor eroding their value. It is natural for humans to develop depressive is natural for humans to develop depressive reactions, which -for most -have the reactions, which -for most -have the tendency to remit, whether spontaneously tendency to remit, whether spontaneously or in response to support or improvement or in response to support or improvement in a stressful situation. Patients with 'cliniin a stressful situation. Patients with 'clinical depression' differ by a distinctly lower cal depression' differ by a distinctly lower likelihood of a 'spontaneous remission', likelihood of a 'spontaneous remission', whether reflecting biological, psychological whether reflecting biological, psychological or social factors. Subjects in clinical trials or social factors. Subjects in clinical trials 1 0 2 1 0 2 (2002) suggesting that response to the (2002) suggesting that response to the newer antidepressants only marginally newer antidepressants only marginally exceeds placebo response is not surprising. exceeds placebo response is not surprising. In summary, current designs restrict the In summary, current designs restrict the participation of 'true' specific responders, participation of 'true' specific responders, being overly weighted towards pristine subbeing overly weighted towards pristine subjects with non-biological depressive disjects with non-biological depressive disorders, with unstable symptomatology orders, with unstable symptomatology and disorders of marginal severity, and and disorders of marginal severity, and disposed to 'respond' irrespective of the disposed to 'respond' irrespective of the treatment arm. Extrapolation of such treatment arm. Extrapolation of such studies to the clinical management of melstudies to the clinical management of melancholic depression, and possibly other ancholic depression, and possibly other 'biological' expressions of depression, is 'biological' expressions of depression, is then illogical. then illogical.
B R I T I S H J O UR N A L O F P SYC HI AT RY B R I T I S H J O UR N A L O F P S YC H I AT RY
Should loss of confidence in trial data Should loss of confidence in trial data lead to their abandonment? Just as it is lead to their abandonment? Just as it is not necessary to abandon religion because not necessary to abandon religion because of antipathy to the local minister, loss of of antipathy to the local minister, loss of faith in clinical trials might more usefully faith in clinical trials might more usefully lead to modifying their faulty components. lead to modifying their faulty components. One strategy would be to reduce the disOne strategy would be to reduce the distance between efficacy studies (assessing tance between efficacy studies (assessing outcome under controlled conditions) and outcome under controlled conditions) and effectiveness studies (approximating to the effectiveness studies (approximating to the clinical world), both by modifying the clinical world), both by modifying the current efficacy study paradigm and by current efficacy study paradigm and by undertaking clinical panel studies. undertaking clinical panel studies.
It is hard to detect any winners from the It is hard to detect any winners from the current paradigm, whether licensing authcurrent paradigm, whether licensing authorities, the pharmaceutical industry or orities, the pharmaceutical industry or patients. Current operational strategies for patients. Current operational strategies for trials are producing specious and irrelevant trials are producing specious and irrelevant information, compromising rationality and information, compromising rationality and reality. They need to get real. reality. They need to get real. , 2002) . It is uncomfortable to have our assumptions uncomfortable to have our assumptions questioned. There is enormous investment questioned. There is enormous investment in our belief that antidepressants work, in our belief that antidepressants work, from its buttressing the scientific basis of from its buttressing the scientific basis of psychiatry, through our need as clinicians psychiatry, through our need as clinicians to have the tools for alleviating distress, to to have the tools for alleviating distress, to providing a financial return for pharmproviding a financial return for pharmaceutical companies. However, as we psyaceutical companies. However, as we psychiatrists know only too well, firmly held chiatrists know only too well, firmly held beliefs may, on occasion, be delusional. beliefs may, on occasion, be delusional. The fact that most people support the The fact that most people support the psychopharmacological orthodoxy is, in psychopharmacological orthodoxy is, in itself, no argument and it is important to itself, no argument and it is important to examine the evidence before drawing examine the evidence before drawing conclusions. conclusions.
Declaration of interest Declaration of interest
Addressing the most forceful criticism, Addressing the most forceful criticism, whether or not antidepressants really work whether or not antidepressants really work (i.e. have a pharmacologically specific (i.e. have a pharmacologically specific action), we do have to turn to RCT eviaction), we do have to turn to RCT evidence as this is the only way to tease out dence as this is the only way to tease out the effects of placebo the effects of placebo v v. drug. The key issue . drug. The key issue is that of publication bias. Kirsch is that of publication bias. Kirsch et al et al (2002) identified all available acute treat-(2002) identified all available acute treatment studies comparing newer antidepresment studies comparing newer antidepressants with placebo in evidence submitted sants with placebo in evidence submitted to the US Food and Drug Administration. to the US Food and Drug Administration. This included previously unreported 'negaThis included previously unreported 'negative' studies and is likely to be as complete tive' studies and is likely to be as complete a data-set as possible. The outcome from a data-set as possible. The outcome from pooling the studies is a highly statistically pooling the studies is a highly statistically significant effect in favour of antidepressignificant effect in favour of antidepressants. Therefore, whatever the size and sants. Therefore, whatever the size and cause of the effect, the central question as cause of the effect, the central question as to whether there really is an effect is to whether there really is an effect is answered in the affirmative. answered in the affirmative.
What is the cause of this effect? What is the cause of this effect? Greenberg Greenberg et al et al (1992) have attributed it (1992) have attributed it to unblinding. In other words, the effect to unblinding. In other words, the effect exists but is due to an enhanced placebo exists but is due to an enhanced placebo effect because patients and/or assessors effect because patients and/or assessors can tell who is receiving the active drug. can tell who is receiving the active drug. Unfortunately, this not an objection that it Unfortunately, this not an objection that it is possible to answer definitively. The is possible to answer definitively. The pharmaceutical industry and trialists have pharmaceutical industry and trialists have done themselves no favours here because done themselves no favours here because the relatively simple process of checking the relatively simple process of checking and reporting the success of blinding is and reporting the success of blinding is rarely done. Nevertheless, strong circumrarely done. Nevertheless, strong circumstantial evidence all points to lack of blindstantial evidence all points to lack of blinding not accounting for the effect (Moncrieff ing not accounting for the effect (Moncrieff et al et al, 1998; Smith , 1998; Smith et al et al, 2002; Geddes , 2002; Geddes et al et al, , 2003 Geddes et al et al, , ). 2003 .
So, at least the Emperor's clothes are So, at least the Emperor's clothes are made of 'real cloth' (Thase, 2002) . Nevermade of 'real cloth' (Thase, 2002) . Nevertheless, we still have to answer the criticism theless, we still have to answer the criticism that the fabric is so 'see-through' that it that the fabric is so 'see-through' that it makes little difference -in other words, makes little difference -in other words, the weaker argument that the antidepresthe weaker argument that the antidepressant effect is so small as to be clinically sant effect is so small as to be clinically unimportant. Kirsch unimportant. Kirsch et al et al (2002) found that (2002) found that 80% of the effect of antidepressants was 80% of the effect of antidepressants was duplicated by placebo, a difference in endduplicated by placebo, a difference in endpoint of about two Hamilton Rating Scale point of about two Hamilton Rating Scale for Depression points, half the size of the for Depression points, half the size of the effect usually reported (e.g. Anderson effect usually reported (e.g. . For most patients, it can be , 2000). For most patients, it can be argued, this is a marginal effect. One argued, this is a marginal effect. One approach at this point is to enter a discusapproach at this point is to enter a discussion about how big an effect is required to sion about how big an effect is required to be clinically important, or to propose difbe clinically important, or to propose differential effects related to patient subgroups ferential effects related to patient subgroups or depression severity. We believe this or depression severity. We believe this fundamentally misses the point; RCTs with fundamentally misses the point; RCTs with soft end-points do not allow us to detersoft end-points do not allow us to determine the size of effect in usual clinical mine the size of effect in usual clinical practice. This is something that evidencepractice. This is something that evidencebased medicine, at least in its current guise, based medicine, at least in its current guise, has misled us about. has misled us about.
Quantification, numbers needed to Quantification, numbers needed to treat, effect sizes extrapolated to clinical treat, effect sizes extrapolated to clinical practice are all based on assumptions that practice are all based on assumptions that are violated in RCTs of antidepressants. are violated in RCTs of antidepressants. First, the assumption that RCT patients First, the assumption that RCT patients are representative of the clinical population are representative of the clinical population is simply untrue (Zimmerman & Posternak, is simply untrue (Zimmerman & Posternak, 2002) . Second, the overall effect size for 2002). Second, the overall effect size for antidepressants may be crucially dependent antidepressants may be crucially dependent on the size of the placebo effect. This is on the size of the placebo effect. This is most evident if change from baseline is used most evident if change from baseline is used as the yardstick as in Kirsch as the yardstick as in Kirsch et al et al (2002) .
. Our position is, therefore, that we Our position is, therefore, that we simply do not know how big the effect of simply do not know how big the effect of antidepressants is in clinical practice antidepressants is in clinical practice because RCTs are not designed to tell us because RCTs are not designed to tell us this. Clinical trials of antidepressants are this. Clinical trials of antidepressants are not producing meaningless results, because not producing meaningless results, because they can tell us which compounds work they can tell us which compounds work (i.e. have efficacy). This is vitally important (i.e. have efficacy). This is vitally important both scientifically and as a cornerstone of both scientifically and as a cornerstone of the regulatory process, designed to ensure the regulatory process, designed to ensure that drugs that are licensed are safe and that drugs that are licensed are safe and have a real effect. What have a real effect. What is is meaningless is meaningless is to ask the trials questions they cannot anto ask the trials questions they cannot answer, such as how well do antidepressants swer, such as how well do antidepressants 1 0 3 1 0 3 work in usual practice (their effectiveness). work in usual practice (their effectiveness). The latter question needs different trial The latter question needs different trial designs from that of the standard RCT. This designs from that of the standard RCT. This is no easy task and is one that will require is no easy task and is one that will require more pragmatic/naturalistic approaches to more pragmatic/naturalistic approaches to be more inclusive, while attempting to minibe more inclusive, while attempting to minimise allocation bias. There needs to be mise allocation bias. There needs to be careful selection of target groups, careful selection of target groups, comparison treatments and duration of comparison treatments and duration of the assessment period. Only then will we the assessment period. Only then will we be able to estimate the real added value be able to estimate the real added value of antidepressants in particular patient of antidepressants in particular patient groups. groups.
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